Inactivation of MGAT2 by genetic manipulation and pharmacological intervention supports the idea that targeting the MAG pathway as a therapeutic for metabolic syndrome is a viable option for inhibiting intestinal TAG synthesis. This evidence concerns the gene MAG and metabolic syndrome.